{rfName}
Hi

Indexed in

License and use

Altmetrics

Analysis of institutional authors

Gijon-Conde TAuthorMorón IAuthor
Share
Publications
>
Article

Hiperlipidemia familiar combinada: documento de consenso

Publicated to:Semergen. 40 (7): 374-380 - 2014-10-01 40(7), DOI: 10.1016/j.semerg.2014.07.007

Authors: Mata P; Alonso R; Ruíz-Garcia A; Díaz-Díaz J; Gonzalez N; Gijon-Conde T; Martinez-Faedo C; Morón I; Arranz E; Aguado R; Argueso R; Pérez de Isla L

Affiliations

Centro de Salud de Goya - Author
Centro de Salud Pinto - Author
Centro de Salud San Blas - Author
Fundación Hipercolesterolemia Familiar - Author
Hospital Abente y Lago - Author
Hospital Clinico San Carlos de Madrid - Author
Hospital de Lugo - Author
Hospital Universitario Central de Asturias - Author
Hospital Universitario de León - Author
Hospital Universitario Fundacion Jimenez Diaz - Author
Hospital Universitario La Paz - Author
Universidad Autónoma - Author
See more

Abstract

Familial combined hyperlipidemia (FCH) is a frequent disorder associated with premature coronary artery disease. It is transmitted in an autosomal dominant manner, although there is not a unique gene involved. The diagnosis is performed using clinical criteria, and variability in lipid phenotype and family history of hyperlipidemia are necessaries. Frequently, the disorder is associated with type2 diabetes mellitus, arterial hypertension and central obesity. Patients with FCH are considered as high cardiovascular risk and the lipid target is an LDL-cholesterol <100mg/dL, and <70mg/dL if cardiovascular disease or type 2 diabetes are present. Patients with FCH require lipid lowering treatment using potent statins and sometimes, combined lipid-lowering treatment. Identification and management of other cardiovascular risk factors as type 2 diabetes and hypertension are fundamental to reduce cardiovascular disease burden. This document gives recommendations for the diagnosis and global treatment of patients with FCH directed to specialists and general practitioners. Copyright © 2014 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España. All rights reserved.

Keywords
cardiovascular diseaseconsensus paperdiabetes mellitus tipo 2documento de consensoenfermedad cardiovascularfamilial combined hyperlipidemiahiperlipidemia familiar combinadahipertensionhypertensionlipid-lowering treatmenttratamiento hipolipemianteCardiovascular diseaseConsensus paperFamilial combined hyperlipidemiaHypertensionLipid-lowering treatmentType 2 diabetes mellitus

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Semergen, Q4 Agency Scopus (SJR), its regional focus and specialization in Family Practice, give it significant recognition in a specific niche of scientific knowledge at an international level.

From a relative perspective, and based on the normalized impact indicator calculated from the Field Citation Ratio (FCR) of the Dimensions source, it yields a value of: 1.67, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-02, the following number of citations:

  • Scopus: 5
  • OpenCitations: 6
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-02:

  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 52 (PlumX).